Assessment of Discounts in the Insulin Gross-to-Net Bubble

Newswise — A new set of studies from University of California San Diego finds the difference between the price tag of insulin and what pharmaceutical manufacturers are getting is predominantly explained by discounts that manufacturers give to insurers to have their drugs covered or placed in the preferred tier of the formulary.

The findings are particularly timely given current Congressional interest in reforming the business practices of pharmacy benefit managers. They also contextualize recently announced price reductions for insulins.

DOI:10.1001/jamanetworkopen.2023.18145

DOI:10.1001/jamahealthforum.2023.1430

# # #